Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: A comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone
Introduction
A recently published report showed that local application of an intrauterine device with high-dose gestagens was superior to systemic treatment in women with endometrial hyperplasia [1]. This may be the result of an exposure to dose being many-fold higher due to the local application [2]. Although the result seemed favorable, only a few earlier studies with intrauterine gestagen device have been performed [3], [4], [5]. Gestagen hormones have a documented antiproliferative effect in the human endometrium in vivo as well as in vitro. Former studies suggest that at least 60% of patients with endometrial hyperplasia will respond to gestagen therapy and various treatment regimens have been given to patients [6], [7], [8], [9], [10]. The secretory changes induced by endogenous progesterone in the normal cycling endometrium are accompanied by various molecular processes, among which apoptosis has shown to be of great importance [10], [11]. Apoptosis or programmed cell death in the histological normal human endometrium after intrauterine levonorgestrel device has also been demonstrated [11]. Although the information of molecular gestagen influence on apoptosis in the human hyperplastic endometrium is incomplete, the complex process of apoptosis has been studied during the last decades in different tissues and cells. The apoptotic cascade has shown to be regulated by extracellular signals or controlled by intracellular autonomous genetic programs [12]. The initial morphological characteristic of apoptosis is cell shrinkage. This observation is in agreement with a former study describing a mean reduction in glandular cell nuclei of the hyperplastic endometrium after gestagen therapy [1]. The controlled and actively regulated cascade of apoptosis leads to cell death by internucleosomal DNA cleavage [13]. The ultimate end-points of apoptosis (apoptotic bodies) as well as the individual proteins of the cascade can be detected by several techniques, like immunohistochemistry and in situ hybridization [10], [11], [14].
One of the most studied anti-apoptotic proteins is Bcl-2, shown to protect cells from apoptosis by regulating mitochondrial membrane function [15], [16]. Another member of the Bcl-2 family, the BAX protein, increases the apoptotic susceptibility of cells in several organs [16]. To further elucidate the biologic sensitivity of apoptotic proteins to gestagens in endometrial hyperplasia, we measured the expression of Bcl-2 and BAX proteins and apoptotic cells in hyperplastic endometrium treated with different gestagen regimens prior to and after 3 months of therapy. In a second group of patients, the effect after 1 week of treatment was determined to detect early effects on Bcl-2 and BAX expression, and apoptotic cells. The changes in endometrial biopsies from patients treated with intrauterine high dose gestagen device were compared to those from patients who received low dose systemic therapy.
Section snippets
Morphometry/D-score measurement
The objective prognostic image analysis algorithm, D-score, was performed for all hyperplasia specimens to decide on individual prognostic risk of cancer development and to exclude the high-risk patients from the study. In the original computerized morphometrical analysis study on endometrial hyperplasia, a total of 10 nuclear features and 12 architectural features were analyzed. Using a linear stepwise regression analysis and discriminant analysis, three of these quantitative features were
Response to 3 months gestagen therapy
Histological response to 3 months gestagen therapy is described in Table 2. After 3 months, all patients treated with gestagen intrauterine device had normalized or atrophic endometrium, whereas 14 of a total of 26 patients had persistent hyperplasia in the group with per oral treatment.
Expression of Bcl-2 in endometrial glands
The levels of Bcl-2 expression were comparable before treatment in the IUD and PO groups (P > 0.05). Fig. 1 (panel A) shows the results. When comparing the mean H-score values of Bcl-2 for the pre- and post
Discussion
In vitro studies have shown that apoptosis is induced by progesterone in highly differentiated endometrial cancer cells [10]. The hypothesis that sex steroids regulated the expression of genes coding for apoptosis-related proteins was forwarded long ago [23]. Knowledge of gestagen-hormone influence on apoptosis was based on the observation of varying expression of apoptotic molecules during the normal cycling endometrium [23], [24]. A considerable variation in the levels of Bcl-2, BAX, and
Acknowledgment
The study has been supported by grants from The Norwegian Cancer Society and the Aakre Cancer Foundation. Valuable assistance with histological pictures has been given by Kurt Larsen.
References (33)
- et al.
Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone
Gynecol. Oncol.
(2003) - et al.
The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia
Am. J. Obstet. Gynecol.
(1989) - et al.
Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40
Obstet. Gynecol.
(1997) - et al.
Apoptosis may be an early event of progestin therapy for endometrial hyperplasia
Gynecol. Oncol.
(2000) - et al.
Apoptosis and apoptosis-related proteins in human endometrium
Mol. Cell. Endocrinol.
(2000) - et al.
Apoptosis, bcl-2 expression, and proliferation in benign and malignant endometrial epithelium: an approach using multiparameter flow cytometry
Gynecol. Oncol.
(2000) - et al.
Expression of bcl-2 oncoprotein in gastrointestinal and uterine carcinomas and their premalignant lesions
Hum. Pathol.
(1997) - et al.
Down-regulation of bcl-2 is a potential marker of the efficacy of progestin therapy in the treatment of endometrial hyperplasia
Gynecol. Oncol.
(1999) - et al.
Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD
Clin. Endocrinol. (Oxford)
(1982) - et al.
Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices
Acta Eur. Fertil.
(1987)
Levo-norgestrel-nova-T and precancerous lesions of the endometrium
Eur. J. Gynaecol. Oncol.
Levonorgestrel IUS-treatment for endometrial cystic hyperplasia
Gynecology
Hormonal therapy for lesions of the endometrium
Semin. Oncol.
Endometrial hyperplasia. Clinico-pathological considerations of a prospective randomised study after abrasio only or high-dose gestagen treatment. Results of 2 years follow-up of 292 patients
Anticancer Res.
Effects of the levonorgestrel-releasing intrauterine system on proliferation and apoptosis in the endometrium
Hum. Reprod.
Apoptosis: the biochemistry and molecular biology of programmed cell death
Endocr. Rev.
Cited by (55)
Efficacy of the LNG-IUS for treatment of endometrial hyperplasia and early stage endometrial cancer: Can biomarkers predict response?
2021, Gynecologic Oncology ReportsEndometrial precancers: From concept to practice
2013, Diagnostic HistopathologyBiomarkers of progestin therapy resistance and endometrial hyperplasia progression
2012, American Journal of Obstetrics and GynecologyCitation Excerpt :Bcl-2 is an antiapoptotic gene that suppresses programmed cell death and is expressed in a variety of human neoplasms.39 Previous studies suggested that Bcl-2 is expressed in the early stage of the neoplastic continuum39-42 and is down-regulated with administration of progesterone.19,22 There are strengths and limitations of our study.
Nonsteroidal antiinflammatory drugs and progestins synergistically enhance cell death in ovarian epithelial cells
2012, American Journal of Obstetrics and GynecologyCitation Excerpt :Pharmacological agents that selectively enhance apoptosis have been shown to lower the risk of a variety of cancers in animals and humans.24 In addition, in animal models of cancer as well as in humans, the efficacy of cancer preventive agents correlates with the degree of apoptosis.24-27 Conversely, mutations in genes involved in the apoptosis pathway are associated with enhanced cancer risk.28
Network pharmacology prediction and experimental verification of Rhubarb-Peach Kernel promoting apoptosis in endometriosis
2023, BMC Complementary Medicine and Therapies